Get App
Download App Scanner
Scan to Download
Advertisement
This Article is From Dec 07, 2011

Ranbaxy’s arm launches authorized generic version of Caduet in US

The product is indicated for patients suffering from both, high blood pressure and high levels of cholesterol

Ranbaxy’s arm launches authorized generic version of Caduet in US
Tough times
The product is indicated for patients suffering from both, high blood pressure and high levels of cholesterol
Athens:

Ranbaxy Laboratories’ wholly owned subsidiary - Ranbaxy Pharmaceuticals Inc. has launched an authorized generic version of Caduet in the US market, as part of an agreement with Pfizer Inc. The product is indicated for patients suffering from both, high blood pressure and high levels of cholesterol.

 

Caduet is a fixed-dose combination of Atorvastatin-Amlodipine besylate, presently marketed by Pfizer under the brand Caduet, which also contains a crystalline form of Atorvastatin. Caduet generated total annual sales of $339 million in the US, as per IMS - MAT September 2011. The company is making available the full range of the generic version of Caduet.

Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay

 

Recently, Ranbaxy Laboratories had received US health regulator’s approval to produce generic version of cholesterol lowering drug Lipitor, a move that will help the India-based firm to launch the drug in the American market.

Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.

Newsletters

Update Email
to get newsletters straight to your inbox
⚠️ Add your Email ID to receive Newsletters
Note: You will be signed up automatically after adding email

News for You

Set as Trusted Source
on Google Search
Listen to the latest songs, only on JioSaavn.com